Next Article in Journal
Soapwort (Saponaria officinalis L.) Extract vs. Synthetic Surfactants—Effect on Skin-Mimetic Models
Next Article in Special Issue
Isolation, Characterization, Complete Structural Assignment, and Anticancer Activities of the Methoxylated Flavonoids from Rhamnus disperma Roots
Previous Article in Journal
Enhanced Activity by Genetic Complementarity: Heterologous Secretion of Clostridial Cellulases by Bacillus licheniformis and Bacillus velezensis
Previous Article in Special Issue
(+)-Usnic Acid as a Promising Candidate for a Safe and Stable Topical Photoprotective Agent
Review

Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses

Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 3, 16628 Prague, Czech Republic
*
Author to whom correspondence should be addressed.
Academic Editor: Robert J. Linhardt
Molecules 2021, 26(18), 5627; https://doi.org/10.3390/molecules26185627
Received: 6 August 2021 / Revised: 13 September 2021 / Accepted: 14 September 2021 / Published: 16 September 2021
(This article belongs to the Special Issue Natural Product-Inspired Molecules: From Weed to Remedy)
Drug repositioning is a successful approach in medicinal research. It significantly simplifies the long-term process of clinical drug evaluation, since the drug being tested has already been approved for another condition. One example of drug repositioning involves cardiac glycosides (CGs), which have, for a long time, been used in heart medicine. Moreover, it has been known for decades that CGs also have great potential in cancer treatment and, thus, many clinical trials now evaluate their anticancer potential. Interestingly, heart failure and cancer are not the only conditions for which CGs could be effectively used. In recent years, the antiviral potential of CGs has been extensively studied, and with the ongoing SARS-CoV-2 pandemic, this interest in CGs has increased even more. Therefore, here, we present CGs as potent and promising antiviral compounds, which can interfere with almost any steps of the viral life cycle, except for the viral attachment to a host cell. In this review article, we summarize the reported data on this hot topic and discuss the mechanisms of antiviral action of CGs, with reference to the particular viral life cycle phase they interfere with. View Full-Text
Keywords: cardiac steroids; digoxin; digitoxin; ouabain; lanatoside C; COVID-19; virus entry; Na+/K+-ATPase; drug repurposing; coronavirus cardiac steroids; digoxin; digitoxin; ouabain; lanatoside C; COVID-19; virus entry; Na+/K+-ATPase; drug repurposing; coronavirus
Show Figures

Graphical abstract

MDPI and ACS Style

Škubník, J.; Bejček, J.; Pavlíčková, V.S.; Rimpelová, S. Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses. Molecules 2021, 26, 5627. https://doi.org/10.3390/molecules26185627

AMA Style

Škubník J, Bejček J, Pavlíčková VS, Rimpelová S. Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses. Molecules. 2021; 26(18):5627. https://doi.org/10.3390/molecules26185627

Chicago/Turabian Style

Škubník, Jan, Jiří Bejček, Vladimíra S. Pavlíčková, and Silvie Rimpelová. 2021. "Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses" Molecules 26, no. 18: 5627. https://doi.org/10.3390/molecules26185627

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop